-+ 0.00%
-+ 0.00%
-+ 0.00%
CG Oncology's cretostimogene cuts bladder cancer recurrence risk by 68% in Phase 3 trial
Share
Listen to the news
CG Oncology's cretostimogene cuts bladder cancer recurrence risk by 68% in Phase 3 trial
  • CG Oncology's Phase 3 PIVOT-006 trial showed cretostimogene significantly reduced recurrence in intermediate-risk and high-grade Ta non-muscle-invasive bladder cancer.
  • Treatment was generally well tolerated, with no treatment-related discontinuations.
  • Topline results will be presented at the Society of Urologic Oncology Annual Meeting on December 2, 2026.
  • The results will support a second biologics license application in intermediate-risk and high-grade Ta disease, expected in Q2 2027.
  • Following FDA feedback, the initial BCG-unresponsive application will add high-grade papillary-only disease; completion is expected by the end of March 2027.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. CG Oncology Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202611160800PRIMZONEFULLFEED9878056) on November 16, 2026, and is solely responsible for the information contained therein.

Disclaimer:This article represents the opinion of the author only. It does not represent the opinion of Webull, nor should it be viewed as an indication that Webull either agrees with or confirms the truthfulness or accuracy of the information. It should not be considered as investment advice from Webull or anyone else, nor should it be used as the basis of any investment decision.
What's Trending